The phase III ARANOTE trial, investigating Nubeqa (darolutamide) plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, has met its primary endpoint of radiological progression-free survival. Nubeqa plus ADT demonstrated a statistically significant and clinically meaningful increase in rPFS compared to placebo plus ADT.
Artera, the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, announced an update to the ArteraAI Prostate Test, enabling clinicians to make more informed decisions about active surveillance when delivering care to prostate cancer patients.
